GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis

Background and purpose Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter‐individual variability exists in the response to GCs. Methods A Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide pol...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of neurology Vol. 23; no. 8; pp. 1372 - 1379
Main Authors Xie, Y., Meng, Y., Li, H.-F., Hong, Y., Sun, L., Zhu, X., Yue, Y.-X., Gao, X., Wang, S., Li, Y., Kusner, L. L., Kaminski, H. J.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.08.2016
John Wiley & Sons, Inc
Subjects
Adult
Alleles
Cohort Studies
Female
Genes
glucocorticoid receptor
Glucocorticoids - therapeutic use
Humans
Male
Middle Aged
myasthenia gravis
Myasthenia Gravis - drug therapy
Myasthenia Gravis - genetics
Pharmacogenetics
Polymorphism, Single Nucleotide
Receptors, Glucocorticoid - genetics
single nucleotide polymorphism
treatment efficacy
variability
myasthenia gravis
glucocorticoid receptor
variability
single nucleotide polymorphism
treatment efficacy
Online AccessGet full text

Cover

Abstract Background and purpose Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter‐individual variability exists in the response to GCs. Methods A Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide polymorphisms in the GR gene and clinical response to the initial 3 month GC therapy. A quantitative MG score decreasing by ≥3 units or becoming zero was defined as sensitivity to GCs. Results The rs17209237* G allele was less frequent in the GC insensitive group compared with the GC sensitive group [P = 0.013, odds ratio (OR) 0.119]. The rs9324921* A allele was more frequent in the GC insensitive group than in the GC sensitive group (P = 0.046, OR 1.94). Carriers of the rs17209237 G allele were less frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.009). Carriers of the rs9324921 A allele were more frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.037). Multivariate logistic regression revealed that the rs17209237 G allele carrier (P = 0.037, OR 0.12) and disease duration before GC treatment (P = 0.011, OR 3.45) were independent factors that contributed to GC efficacy. Conclusion rs17209237 in the GR gene was identified as an independent factor that contributes to GC efficacy in MG patients. The genetic variations of the GR gene may play a role in predicting response to GC treatment.
AbstractList Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the response to GCs.BACKGROUND AND PURPOSEGlucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the response to GCs.A Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide polymorphisms in the GR gene and clinical response to the initial 3 month GC therapy. A quantitative MG score decreasing by ≥3 units or becoming zero was defined as sensitivity to GCs.METHODSA Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide polymorphisms in the GR gene and clinical response to the initial 3 month GC therapy. A quantitative MG score decreasing by ≥3 units or becoming zero was defined as sensitivity to GCs.The rs17209237* G allele was less frequent in the GC insensitive group compared with the GC sensitive group [P = 0.013, odds ratio (OR) 0.119]. The rs9324921* A allele was more frequent in the GC insensitive group than in the GC sensitive group (P = 0.046, OR 1.94). Carriers of the rs17209237 G allele were less frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.009). Carriers of the rs9324921 A allele were more frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.037). Multivariate logistic regression revealed that the rs17209237 G allele carrier (P = 0.037, OR 0.12) and disease duration before GC treatment (P = 0.011, OR 3.45) were independent factors that contributed to GC efficacy.RESULTSThe rs17209237* G allele was less frequent in the GC insensitive group compared with the GC sensitive group [P = 0.013, odds ratio (OR) 0.119]. The rs9324921* A allele was more frequent in the GC insensitive group than in the GC sensitive group (P = 0.046, OR 1.94). Carriers of the rs17209237 G allele were less frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.009). Carriers of the rs9324921 A allele were more frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.037). Multivariate logistic regression revealed that the rs17209237 G allele carrier (P = 0.037, OR 0.12) and disease duration before GC treatment (P = 0.011, OR 3.45) were independent factors that contributed to GC efficacy.rs17209237 in the GR gene was identified as an independent factor that contributes to GC efficacy in MG patients. The genetic variations of the GR gene may play a role in predicting response to GC treatment.CONCLUSIONrs17209237 in the GR gene was identified as an independent factor that contributes to GC efficacy in MG patients. The genetic variations of the GR gene may play a role in predicting response to GC treatment.
Background and purpose Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the response to GCs. Methods A Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide polymorphisms in the GR gene and clinical response to the initial 3 month GC therapy. A quantitative MG score decreasing by greater than or equal to 3 units or becoming zero was defined as sensitivity to GCs. Results The rs17209237* G allele was less frequent in the GC insensitive group compared with the GC sensitive group [P = 0.013, odds ratio (OR) 0.119]. The rs9324921* A allele was more frequent in the GC insensitive group than in the GC sensitive group (P = 0.046, OR 1.94). Carriers of the rs17209237 G allele were less frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.009). Carriers of the rs9324921 A allele were more frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.037). Multivariate logistic regression revealed that the rs17209237 G allele carrier (P = 0.037, OR 0.12) and disease duration before GC treatment (P = 0.011, OR 3.45) were independent factors that contributed to GC efficacy. Conclusion rs17209237 in the GR gene was identified as an independent factor that contributes to GC efficacy in MG patients. The genetic variations of the GR gene may play a role in predicting response to GC treatment.
Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the response to GCs. A Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide polymorphisms in the GR gene and clinical response to the initial 3 month GC therapy. A quantitative MG score decreasing by ≥3 units or becoming zero was defined as sensitivity to GCs. The rs17209237* G allele was less frequent in the GC insensitive group compared with the GC sensitive group [P = 0.013, odds ratio (OR) 0.119]. The rs9324921* A allele was more frequent in the GC insensitive group than in the GC sensitive group (P = 0.046, OR 1.94). Carriers of the rs17209237 G allele were less frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.009). Carriers of the rs9324921 A allele were more frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.037). Multivariate logistic regression revealed that the rs17209237 G allele carrier (P = 0.037, OR 0.12) and disease duration before GC treatment (P = 0.011, OR 3.45) were independent factors that contributed to GC efficacy. rs17209237 in the GR gene was identified as an independent factor that contributes to GC efficacy in MG patients. The genetic variations of the GR gene may play a role in predicting response to GC treatment.
Background and purpose Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the response to GCs. Methods A Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide polymorphisms in the GR gene and clinical response to the initial 3 month GC therapy. A quantitative MG score decreasing by ≥3 units or becoming zero was defined as sensitivity to GCs. Results The rs17209237* G allele was less frequent in the GC insensitive group compared with the GC sensitive group [P = 0.013, odds ratio (OR) 0.119]. The rs9324921* A allele was more frequent in the GC insensitive group than in the GC sensitive group (P = 0.046, OR 1.94). Carriers of the rs17209237 G allele were less frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.009). Carriers of the rs9324921 A allele were more frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.037). Multivariate logistic regression revealed that the rs17209237 G allele carrier (P = 0.037, OR 0.12) and disease duration before GC treatment (P = 0.011, OR 3.45) were independent factors that contributed to GC efficacy. Conclusion rs17209237 in the GR gene was identified as an independent factor that contributes to GC efficacy in MG patients. The genetic variations of the GR gene may play a role in predicting response to GC treatment.
Background and purpose Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter‐individual variability exists in the response to GCs. Methods A Chinese cohort of 257 MG patients treated with GCs was evaluated for the association between 19 single nucleotide polymorphisms in the GR gene and clinical response to the initial 3 month GC therapy. A quantitative MG score decreasing by ≥3 units or becoming zero was defined as sensitivity to GCs. Results The rs17209237* G allele was less frequent in the GC insensitive group compared with the GC sensitive group [P = 0.013, odds ratio (OR) 0.119]. The rs9324921* A allele was more frequent in the GC insensitive group than in the GC sensitive group (P = 0.046, OR 1.94). Carriers of the rs17209237 G allele were less frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.009). Carriers of the rs9324921 A allele were more frequent in the GC insensitive group than in the GC sensitive group (dominant model, P = 0.037). Multivariate logistic regression revealed that the rs17209237 G allele carrier (P = 0.037, OR 0.12) and disease duration before GC treatment (P = 0.011, OR 3.45) were independent factors that contributed to GC efficacy. Conclusion rs17209237 in the GR gene was identified as an independent factor that contributes to GC efficacy in MG patients. The genetic variations of the GR gene may play a role in predicting response to GC treatment.
Author Hong, Y.
Wang, S.
Xie, Y.
Li, Y.
Li, H.-F.
Sun, L.
Kaminski, H. J.
Meng, Y.
Gao, X.
Zhu, X.
Yue, Y.-X.
Kusner, L. L.
Author_xml – sequence: 1
  givenname: Y.
  surname: Xie
  fullname: Xie, Y.
  organization: Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
– sequence: 2
  givenname: Y.
  surname: Meng
  fullname: Meng, Y.
  organization: Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China
– sequence: 3
  givenname: H.-F.
  surname: Li
  fullname: Li, H.-F.
  email: drlhf@163.comhkaminski@mfa.gwu.edu
  organization: Department of Neurology, Qilu Hospital of Shandong University, Jinan, China
– sequence: 4
  givenname: Y.
  surname: Hong
  fullname: Hong, Y.
  organization: Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China
– sequence: 5
  givenname: L.
  surname: Sun
  fullname: Sun, L.
  organization: Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics, Ministry of Health, Beijing, China
– sequence: 6
  givenname: X.
  surname: Zhu
  fullname: Zhu, X.
  organization: Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics, Ministry of Health, Beijing, China
– sequence: 7
  givenname: Y.-X.
  surname: Yue
  fullname: Yue, Y.-X.
  organization: Department of Neurology, Qilu Hospital of Shandong University, Jinan, China
– sequence: 8
  givenname: X.
  surname: Gao
  fullname: Gao, X.
  organization: Department of Neurology, Affiliated Hospital of Qingdao University, Qingdao, China
– sequence: 9
  givenname: S.
  surname: Wang
  fullname: Wang, S.
  organization: Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
– sequence: 10
  givenname: Y.
  surname: Li
  fullname: Li, Y.
  organization: Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
– sequence: 11
  givenname: L. L.
  surname: Kusner
  fullname: Kusner, L. L.
  organization: Departments of Pharmacology and Physiology, George Washington University, DC, Washington, USA
– sequence: 12
  givenname: H. J.
  surname: Kaminski
  fullname: Kaminski, H. J.
  email: drlhf@163.comhkaminski@mfa.gwu.edu
  organization: Department of Neurology, George Washington University, DC, Washington, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27185333$$D View this record in MEDLINE/PubMed
BookMark eNqNkUtv1DAURi1URB-w4A8gS2xgkdaOndeSVsPwqIaHQLCzHNuZ8ZDYwddpyZo_jttpu6gEwhtbuud80vV3iPacdwahp5Qc03ROjDPHlBFOHqADyss6o4zRvfRmBc0KSug-OgTYEkLyKieP0H5e0bpgjB2g38vPeJ18PPp-HnwYNxYGbAFLAK-sjEbjSxs32LpoQgZTuzUq4gsZrGxtb-OcJjgYGL0Dg6PH635SXvkQrfJWw9V4lNEaF2GXNMwS4sY4K_E6yAsLj9HDTvZgntzcR-jr68WXszfZ-Yfl27NX55niDScZ17phtSS67HRetmWp2o40tNV5VXSVllXZdpLmTVt2kjeUU0lyXWvdKUqTRNgRerHLHYP_ORmIYrCgTN9LZ_wEgtakLllT1-x_0KIqmpLzhD6_h279FFxa5JrKGU9cop7dUFM7GC3GYAcZZnHbRAJe7gAVPEAw3R1CibhqWaSWxHXLiT25xyob0x97F4O0_b-MS9ub-e_RYrFa3BrZzrAQza87Q4YfoqxYVYhvq6X4ePr-3epT_l2s2B8yrMkm
CODEN EJNEFL
CitedBy_id crossref_primary_10_1097_MD_0000000000006798
crossref_primary_10_1007_s10792_023_02676_4
crossref_primary_10_1016_j_autrev_2022_103104
crossref_primary_10_1016_j_amjoto_2018_11_002
crossref_primary_10_1080_23808993_2020_1804865
crossref_primary_10_1016_j_cytogfr_2017_04_002
crossref_primary_10_1016_j_jneuroim_2023_578269
crossref_primary_10_3390_cells10113186
crossref_primary_10_1016_j_jad_2021_10_002
crossref_primary_10_1371_journal_pone_0287654
crossref_primary_10_1016_j_jsbmb_2021_105952
crossref_primary_10_3389_fneur_2017_00230
crossref_primary_10_1111_ene_13480
crossref_primary_10_3389_fneur_2022_886625
crossref_primary_10_1111_1756_185X_13191
crossref_primary_10_3389_fneur_2022_880040
crossref_primary_10_1172_JCI179742
crossref_primary_10_59598_ME_2305_6045_2023_106_1_12_26
crossref_primary_10_1002_ardp_201700371
crossref_primary_10_1080_14737175_2018_1491310
Cites_doi 10.1186/1479-5876-7-81
10.1016/j.mce.2008.10.001
10.1111/j.1749-6632.2009.05013.x
10.1172/JCI117943
10.1016/S1474-4422(09)70063-8
10.1038/nrendo.2013.183
10.1111/j.1749-6632.1998.tb11015.x
10.1074/jbc.R110.179325
10.1210/jc.2003-030995
10.1016/j.ejphar.2007.11.072
10.1007/s11033-010-0512-5
10.1212/WNL.55.1.7
10.1007/s10620-012-2293-2
10.1016/j.tips.2013.07.003
10.1007/s00296-015-3235-z
10.1111/j.1469-1809.2008.00469.x
10.1007/s11910-010-0151-1
10.1038/318635a0
10.1097/FPC.0b013e3283476a01
10.1016/j.steroids.2014.07.015
10.1212/01.WNL.0000163988.28892.79
10.1007/s00439-006-0180-7
10.1212/WNL.55.1.16
10.1111/j.1468-1331.2010.03019.x
10.1016/S0021-9258(20)89627-6
10.1210/jc.2005-1893
10.1196/annals.1351.001
10.1196/annals.1405.040
10.1016/j.steroids.2009.09.002
10.3109/08916934.2013.830714
10.1001/archneur.60.2.243
10.1159/000116785
10.1002/ana.410150316
ContentType Journal Article
Copyright 2016 EAN
2016 EAN.
European Journal of Neurology © 2016 European Academy of Neurology
Copyright_xml – notice: 2016 EAN
– notice: 2016 EAN.
– notice: European Journal of Neurology © 2016 European Academy of Neurology
DBID BSCLL
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
C1K
K9.
7X8
DOI 10.1111/ene.13040
DatabaseName Istex
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
Toxicology Abstracts
Environmental Sciences and Pollution Management
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Toxicology Abstracts
Neurosciences Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Neurosciences Abstracts
MEDLINE
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1468-1331
EndPage 1379
ExternalDocumentID 4121098781
27185333
10_1111_ene_13040
ENE13040
ark_67375_WNG_PBKJNQ2X_N
Genre article
Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  funderid: 81070963; 81400068
– fundername: Shandong Provincial Natural Science Foundation
  funderid: ZR2010HM019
– fundername: Beijing Natural Science Foundation
  funderid: 7142042
GroupedDBID ---
.3N
.GA
.Y3
05W
0R~
10A
169
1OB
1OC
24P
29G
31~
33P
36B
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5VS
66C
702
7PT
7X7
8-0
8-1
8-3
8-4
8-5
8FI
8FJ
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABIVO
ABJNI
ABPVW
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADPDF
ADXAS
ADZMN
ADZOD
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFGKR
AFKRA
AFPWT
AFRAH
AFZJQ
AHMBA
AIACR
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BDRZF
BENPR
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
EBS
EJD
EMOBN
ESX
EX3
F00
F5P
FEDTE
FUBAC
FYBCS
FYUFA
G-S
G.N
GODZA
H.X
HF~
HMCUK
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OVD
OVEED
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIG
RIWAO
RJQFR
ROL
RPM
RX1
SAMSI
SUPJJ
TEORI
UB1
UKHRP
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WOHZO
WOW
WQJ
WVDHM
WXI
WXSBR
XG1
YFH
ZZTAW
~IA
~WT
AANHP
AAYCA
ACCMX
ACRPL
ACYXJ
ADNMO
AFWVQ
AAYXX
AGQPQ
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7U7
C1K
K9.
7X8
ID FETCH-LOGICAL-c4940-4dd938a0d6fd26b66cbf091bd275f7da76bfa129b6fa49141a02d8ddfc110d603
IEDL.DBID DR2
ISSN 1351-5101
1468-1331
IngestDate Fri Jul 11 14:35:12 EDT 2025
Thu Jul 10 23:36:53 EDT 2025
Sat Jul 26 02:26:15 EDT 2025
Mon Jul 21 05:55:39 EDT 2025
Tue Jul 01 02:47:43 EDT 2025
Thu Apr 24 23:11:44 EDT 2025
Wed Jan 22 16:27:03 EST 2025
Wed Oct 30 09:57:46 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords myasthenia gravis
glucocorticoid receptor
variability
single nucleotide polymorphism
treatment efficacy
Language English
License 2016 EAN.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4940-4dd938a0d6fd26b66cbf091bd275f7da76bfa129b6fa49141a02d8ddfc110d603
Notes Table S1. Nineteen SNPs associated with a beneficial effect of glucocorticoid therapy.
Shandong Provincial Natural Science Foundation - No. ZR2010HM019
ArticleID:ENE13040
National Natural Science Foundation of China - No. 81070963; No. 81400068
ark:/67375/WNG-PBKJNQ2X-N
Beijing Natural Science Foundation - No. 7142042
istex:91778F688F82E14015F0592E5EE620F3B217AF97
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
PMID 27185333
PQID 1805234596
PQPubID 1066358
PageCount 8
ParticipantIDs proquest_miscellaneous_1808639883
proquest_miscellaneous_1805759644
proquest_journals_1805234596
pubmed_primary_27185333
crossref_primary_10_1111_ene_13040
crossref_citationtrail_10_1111_ene_13040
wiley_primary_10_1111_ene_13040_ENE13040
istex_primary_ark_67375_WNG_PBKJNQ2X_N
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate August 2016
PublicationDateYYYYMMDD 2016-08-01
PublicationDate_xml – month: 08
  year: 2016
  text: August 2016
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle European journal of neurology
PublicationTitleAlternate Eur J Neurol
PublicationYear 2016
Publisher Blackwell Publishing Ltd
John Wiley & Sons, Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley & Sons, Inc
References Pietras T, Panek M, Tworek D, et al. The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: pilot study. Mol Biol Rep 2011; 38: 3953-3958.
Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013; 34: 518-530.
Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-490.
Krupoves A, Mack D, Deslandres C, Seidman E, Amre DK. Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn's disease. Pharmacogenet Genomics 2011; 21: 454-460.
Chen HL, Li LR. Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta-analysis. Dig Dis Sci 2012; 57: 3065-3075.
Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902.
Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-641.
Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998; 841: 769-772.
Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008; 1132: 238-243.
Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243-248.
Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75: 1-12.
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55: 16-23.
Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15.
Quax RA, Koper JW, Huisman AM, et al. Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis. Rheumatol Int 2015; 35: 1325-1333.
Encío IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991; 266: 7182-7188.
Han B, Kang HM, Seo MS, Zaitlen N, Eskin E. Efficient association study design via power-optimized tag SNP selection. Ann Hum Genet 2008; 72: 834-847.
Syed AA, Irving JA, Redfern CP, et al. Low prevalence of the N363S polymorphism of the glucocorticoid receptor in South Asians living in the United Kingdom. J Clin Endocrinol Metab 2004; 89: 232-235.
Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci 2006; 1069: 1-9.
Wang LL, Xie YC, Hou SF, et al. Association of glucocorticoid receptor gene polymorphism with myasthenia gravis. Zhonghua Kou Qiang Yi Xue Za Zhi 2009; 89: 3035-3037.
Derijk RH, de Kloet ER. Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol 2008; 583: 303-311.
Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37-43.
Huang LC, Hsu SY, Lin E. A comparison of classification methods for predicting chronic fatigue syndrome based on genetic data. J Transl Med 2009; 7: 81.
Chen JM, Férec C, Cooper DN. A systematic analysis of disease-associated variants in the 3′ regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006; 120: 1-21.
Quax RA, Manenschijn L, Koper JW, et al. Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol 2013; 9: 670-686.
Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 2011; 11: 89-96.
Oakley RH, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 2011; 286: 3177-3184.
Charmandari E, Kino T, Ichijo T, Zachman K, Alatsatianos A, Chrousos GP. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance. J Clin Endocrinol Metab 2006; 91: 1535-1543.
Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 2009; 1179: 179-198.
Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300: 7-16.
Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291-298.
Koper JW, van Rossum EF, van den Akker EL. Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids 2014; 92: 62-73.
Zou YF, Xu JH, Wang F, et al. Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. Autoimmunity 2013; 46: 531-536.
Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005; 64: 1968-1970.
Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435-2441.
2008; 1132
2015; 35
2009; 89
1995; 95
2006; 91
2010; 75
2014; 92
2013; 46
2010; 17
2004; 89
2011; 11
2005; 64
2006; 1069
2008; 72
1992; 32
2012; 57
2011; 38
2008; 583
2013; 9
1991; 266
1985; 318
1984; 15
2013; 34
2000; 55
2009; 8
2011; 21
2009; 300
2006; 120
1998; 841
2009; 7
2003; 60
2009; 1179
2011; 286
e_1_2_7_6_1
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
Wang LL (e_1_2_7_30_1) 2009; 89
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
e_1_2_7_28_1
e_1_2_7_29_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
Encío IJ (e_1_2_7_8_1) 1991; 266
References_xml – reference: Kupersmith MJ, Latkany R, Homel P. Development of generalized disease at 2 years in patients with ocular myasthenia gravis. Arch Neurol 2003; 60: 243-248.
– reference: Evoli A, Batocchi AP, Palmisani MT, Lo Monaco M, Tonali P. Long-term results of corticosteroid therapy in patients with myasthenia gravis. Eur Neurol 1992; 32: 37-43.
– reference: Charmandari E, Kino T, Ichijo T, Zachman K, Alatsatianos A, Chrousos GP. Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance. J Clin Endocrinol Metab 2006; 91: 1535-1543.
– reference: Kumar V, Kaminski HJ. Treatment of myasthenia gravis. Curr Neurol Neurosci Rep 2011; 11: 89-96.
– reference: Syed AA, Irving JA, Redfern CP, et al. Low prevalence of the N363S polymorphism of the glucocorticoid receptor in South Asians living in the United Kingdom. J Clin Endocrinol Metab 2004; 89: 232-235.
– reference: Pietras T, Panek M, Tworek D, et al. The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: pilot study. Mol Biol Rep 2011; 38: 3953-3958.
– reference: Krupoves A, Mack D, Deslandres C, Seidman E, Amre DK. Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn's disease. Pharmacogenet Genomics 2011; 21: 454-460.
– reference: Gross KL, Lu NZ, Cidlowski JA. Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Mol Cell Endocrinol 2009; 300: 7-16.
– reference: Chen JM, Férec C, Cooper DN. A systematic analysis of disease-associated variants in the 3′ regulatory regions of human protein-coding genes I: general principles and overview. Hum Genet 2006; 120: 1-21.
– reference: Quax RA, Koper JW, Huisman AM, et al. Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis. Rheumatol Int 2015; 35: 1325-1333.
– reference: Zou YF, Xu JH, Wang F, et al. Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. Autoimmunity 2013; 46: 531-536.
– reference: Bamberger CM, Bamberger AM, de Castro M, Chrousos GP. Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans. J Clin Invest 1995; 95: 2435-2441.
– reference: Chen HL, Li LR. Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta-analysis. Dig Dis Sci 2012; 57: 3065-3075.
– reference: Bedlack RS, Simel DL, Bosworth H, Samsa G, Tucker-Lipscomb B, Sanders DB. Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity. Neurology 2005; 64: 1968-1970.
– reference: Oakley RH, Cidlowski JA. Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue-specific actions of glucocorticoids. J Biol Chem 2011; 286: 3177-3184.
– reference: Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8: 475-490.
– reference: Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998; 841: 769-772.
– reference: Pascuzzi RM, Coslett HB, Johns TR. Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol 1984; 15: 291-298.
– reference: Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000; 55: 16-23.
– reference: Gronseth GS, Barohn RJ. Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55: 7-15.
– reference: Huang LC, Hsu SY, Lin E. A comparison of classification methods for predicting chronic fatigue syndrome based on genetic data. J Transl Med 2009; 7: 81.
– reference: Derijk RH, de Kloet ER. Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience. Eur J Pharmacol 2008; 583: 303-311.
– reference: Nicolaides NC, Galata Z, Kino T, Chrousos GP, Charmandari E. The human glucocorticoid receptor: molecular basis of biologic function. Steroids 2010; 75: 1-12.
– reference: Aarli JA. Myasthenia gravis in the elderly: is it different? Ann N Y Acad Sci 2008; 1132: 238-243.
– reference: Wang LL, Xie YC, Hou SF, et al. Association of glucocorticoid receptor gene polymorphism with myasthenia gravis. Zhonghua Kou Qiang Yi Xue Za Zhi 2009; 89: 3035-3037.
– reference: Lewis-Tuffin LJ, Cidlowski JA. The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance. Ann N Y Acad Sci 2006; 1069: 1-9.
– reference: Encío IJ, Detera-Wadleigh SD. The genomic structure of the human glucocorticoid receptor. J Biol Chem 1991; 266: 7182-7188.
– reference: Manenschijn L, van den Akker EL, Lamberts SW, van Rossum EF. Clinical features associated with glucocorticoid receptor polymorphisms. An overview. Ann N Y Acad Sci 2009; 1179: 179-198.
– reference: Kadmiel M, Cidlowski JA. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci 2013; 34: 518-530.
– reference: Koper JW, van Rossum EF, van den Akker EL. Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease. Steroids 2014; 92: 62-73.
– reference: Han B, Kang HM, Seo MS, Zaitlen N, Eskin E. Efficient association study design via power-optimized tag SNP selection. Ann Hum Genet 2008; 72: 834-847.
– reference: Quax RA, Manenschijn L, Koper JW, et al. Glucocorticoid sensitivity in health and disease. Nat Rev Endocrinol 2013; 9: 670-686.
– reference: Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902.
– reference: Hollenberg SM, Weinberger C, Ong ES, et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 1985; 318: 635-641.
– volume: 72
  start-page: 834
  year: 2008
  end-page: 847
  article-title: Efficient association study design via power‐optimized tag SNP selection
  publication-title: Ann Hum Genet
– volume: 35
  start-page: 1325
  year: 2015
  end-page: 1333
  article-title: Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid‐induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis
  publication-title: Rheumatol Int
– volume: 38
  start-page: 3953
  year: 2011
  end-page: 3958
  article-title: The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h‐GR/NR3C1 promoter in patients with bronchial asthma: pilot study
  publication-title: Mol Biol Rep
– volume: 55
  start-page: 16
  year: 2000
  end-page: 23
  article-title: Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America
  publication-title: Neurology
– volume: 75
  start-page: 1
  year: 2010
  end-page: 12
  article-title: The human glucocorticoid receptor: molecular basis of biologic function
  publication-title: Steroids
– volume: 21
  start-page: 454
  year: 2011
  end-page: 460
  article-title: Variation in the glucocorticoid receptor gene (NR3C1) may be associated with corticosteroid dependency and resistance in children with Crohn's disease
  publication-title: Pharmacogenet Genomics
– volume: 583
  start-page: 303
  year: 2008
  end-page: 311
  article-title: Corticosteroid receptor polymorphisms: determinants of vulnerability and resilience
  publication-title: Eur J Pharmacol
– volume: 64
  start-page: 1968
  year: 2005
  end-page: 1970
  article-title: Quantitative myasthenia gravis score: assessment of responsiveness and longitudinal validity
  publication-title: Neurology
– volume: 841
  start-page: 769
  year: 1998
  end-page: 772
  article-title: Reliability testing of the quantitative myasthenia gravis score
  publication-title: Ann N Y Acad Sci
– volume: 300
  start-page: 7
  year: 2009
  end-page: 16
  article-title: Molecular mechanisms regulating glucocorticoid sensitivity and resistance
  publication-title: Mol Cell Endocrinol
– volume: 91
  start-page: 1535
  year: 2006
  end-page: 1543
  article-title: Functional characterization of the natural human glucocorticoid receptor (hGR) mutants hGRalphaR477H and hGRalphaG679S associated with generalized glucocorticoid resistance
  publication-title: J Clin Endocrinol Metab
– volume: 11
  start-page: 89
  year: 2011
  end-page: 96
  article-title: Treatment of myasthenia gravis
  publication-title: Curr Neurol Neurosci Rep
– volume: 120
  start-page: 1
  year: 2006
  end-page: 21
  article-title: A systematic analysis of disease‐associated variants in the 3′ regulatory regions of human protein‐coding genes I: general principles and overview
  publication-title: Hum Genet
– volume: 60
  start-page: 243
  year: 2003
  end-page: 248
  article-title: Development of generalized disease at 2 years in patients with ocular myasthenia gravis
  publication-title: Arch Neurol
– volume: 266
  start-page: 7182
  year: 1991
  end-page: 7188
  article-title: The genomic structure of the human glucocorticoid receptor
  publication-title: J Biol Chem
– volume: 1069
  start-page: 1
  year: 2006
  end-page: 9
  article-title: The physiology of human glucocorticoid receptor beta (hGRbeta) and glucocorticoid resistance
  publication-title: Ann N Y Acad Sci
– volume: 15
  start-page: 291
  year: 1984
  end-page: 298
  article-title: Long‐term corticosteroid treatment of myasthenia gravis: report of 116 patients
  publication-title: Ann Neurol
– volume: 9
  start-page: 670
  year: 2013
  end-page: 686
  article-title: Glucocorticoid sensitivity in health and disease
  publication-title: Nat Rev Endocrinol
– volume: 89
  start-page: 232
  year: 2004
  end-page: 235
  article-title: Low prevalence of the N363S polymorphism of the glucocorticoid receptor in South Asians living in the United Kingdom
  publication-title: J Clin Endocrinol Metab
– volume: 1132
  start-page: 238
  year: 2008
  end-page: 243
  article-title: Myasthenia gravis in the elderly: is it different?
  publication-title: Ann N Y Acad Sci
– volume: 286
  start-page: 3177
  year: 2011
  end-page: 3184
  article-title: Cellular processing of the glucocorticoid receptor gene and protein: new mechanisms for generating tissue‐specific actions of glucocorticoids
  publication-title: J Biol Chem
– volume: 318
  start-page: 635
  year: 1985
  end-page: 641
  article-title: Primary structure and expression of a functional human glucocorticoid receptor cDNA
  publication-title: Nature
– volume: 7
  start-page: 81
  year: 2009
  article-title: A comparison of classification methods for predicting chronic fatigue syndrome based on genetic data
  publication-title: J Transl Med
– volume: 89
  start-page: 3035
  year: 2009
  end-page: 3037
  article-title: Association of glucocorticoid receptor gene polymorphism with myasthenia gravis
  publication-title: Zhonghua Kou Qiang Yi Xue Za Zhi
– volume: 92
  start-page: 62
  year: 2014
  end-page: 73
  article-title: Glucocorticoid receptor polymorphisms and haplotypes and their expression in health and disease
  publication-title: Steroids
– volume: 46
  start-page: 531
  year: 2013
  end-page: 536
  article-title: Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study
  publication-title: Autoimmunity
– volume: 1179
  start-page: 179
  year: 2009
  end-page: 198
  article-title: Clinical features associated with glucocorticoid receptor polymorphisms. An overview
  publication-title: Ann N Y Acad Sci
– volume: 8
  start-page: 475
  year: 2009
  end-page: 490
  article-title: Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
  publication-title: Lancet Neurol
– volume: 17
  start-page: 893
  year: 2010
  end-page: 902
  article-title: Guidelines for treatment of autoimmune neuromuscular transmission disorders
  publication-title: Eur J Neurol
– volume: 55
  start-page: 7
  year: 2000
  end-page: 15
  article-title: Practice parameter: Thymectomy for autoimmune myasthenia gravis (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
  publication-title: Neurology
– volume: 57
  start-page: 3065
  year: 2012
  end-page: 3075
  article-title: Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta‐analysis
  publication-title: Dig Dis Sci
– volume: 34
  start-page: 518
  year: 2013
  end-page: 530
  article-title: Glucocorticoid receptor signaling in health and disease
  publication-title: Trends Pharmacol Sci
– volume: 95
  start-page: 2435
  year: 1995
  end-page: 2441
  article-title: Glucocorticoid receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans
  publication-title: J Clin Invest
– volume: 32
  start-page: 37
  year: 1992
  end-page: 43
  article-title: Long‐term results of corticosteroid therapy in patients with myasthenia gravis
  publication-title: Eur Neurol
– ident: e_1_2_7_20_1
  doi: 10.1186/1479-5876-7-81
– ident: e_1_2_7_26_1
  doi: 10.1016/j.mce.2008.10.001
– ident: e_1_2_7_9_1
  doi: 10.1111/j.1749-6632.2009.05013.x
– ident: e_1_2_7_24_1
  doi: 10.1172/JCI117943
– ident: e_1_2_7_2_1
  doi: 10.1016/S1474-4422(09)70063-8
– ident: e_1_2_7_7_1
  doi: 10.1038/nrendo.2013.183
– ident: e_1_2_7_15_1
  doi: 10.1111/j.1749-6632.1998.tb11015.x
– ident: e_1_2_7_21_1
  doi: 10.1074/jbc.R110.179325
– ident: e_1_2_7_29_1
  doi: 10.1210/jc.2003-030995
– ident: e_1_2_7_32_1
  doi: 10.1016/j.ejphar.2007.11.072
– ident: e_1_2_7_33_1
  doi: 10.1007/s11033-010-0512-5
– ident: e_1_2_7_35_1
  doi: 10.1212/WNL.55.1.7
– ident: e_1_2_7_11_1
  doi: 10.1007/s10620-012-2293-2
– ident: e_1_2_7_28_1
  doi: 10.1016/j.tips.2013.07.003
– ident: e_1_2_7_27_1
  doi: 10.1007/s00296-015-3235-z
– ident: e_1_2_7_17_1
  doi: 10.1111/j.1469-1809.2008.00469.x
– ident: e_1_2_7_3_1
  doi: 10.1007/s11910-010-0151-1
– ident: e_1_2_7_22_1
  doi: 10.1038/318635a0
– ident: e_1_2_7_19_1
  doi: 10.1097/FPC.0b013e3283476a01
– ident: e_1_2_7_10_1
  doi: 10.1016/j.steroids.2014.07.015
– ident: e_1_2_7_16_1
  doi: 10.1212/01.WNL.0000163988.28892.79
– volume: 89
  start-page: 3035
  year: 2009
  ident: e_1_2_7_30_1
  article-title: Association of glucocorticoid receptor gene polymorphism with myasthenia gravis
  publication-title: Zhonghua Kou Qiang Yi Xue Za Zhi
– ident: e_1_2_7_31_1
  doi: 10.1007/s00439-006-0180-7
– ident: e_1_2_7_14_1
  doi: 10.1212/WNL.55.1.16
– ident: e_1_2_7_6_1
  doi: 10.1111/j.1468-1331.2010.03019.x
– volume: 266
  start-page: 7182
  year: 1991
  ident: e_1_2_7_8_1
  article-title: The genomic structure of the human glucocorticoid receptor
  publication-title: J Biol Chem
  doi: 10.1016/S0021-9258(20)89627-6
– ident: e_1_2_7_18_1
  doi: 10.1210/jc.2005-1893
– ident: e_1_2_7_25_1
  doi: 10.1196/annals.1351.001
– ident: e_1_2_7_13_1
  doi: 10.1196/annals.1405.040
– ident: e_1_2_7_23_1
  doi: 10.1016/j.steroids.2009.09.002
– ident: e_1_2_7_12_1
  doi: 10.3109/08916934.2013.830714
– ident: e_1_2_7_34_1
  doi: 10.1001/archneur.60.2.243
– ident: e_1_2_7_5_1
  doi: 10.1159/000116785
– ident: e_1_2_7_4_1
  doi: 10.1002/ana.410150316
SSID ssj0002720
Score 2.2919784
Snippet Background and purpose Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter‐individual variability exists in the...
Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the response to GCs. A Chinese...
Background and purpose Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the...
Glucocorticoids (GCs) are the mainstay treatment of myasthenia gravis (MG). However, wide inter-individual variability exists in the response to GCs.BACKGROUND...
SourceID proquest
pubmed
crossref
wiley
istex
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1372
SubjectTerms Adult
Alleles
Cohort Studies
Female
Genes
glucocorticoid receptor
Glucocorticoids - therapeutic use
Humans
Male
Middle Aged
myasthenia gravis
Myasthenia Gravis - drug therapy
Myasthenia Gravis - genetics
Pharmacogenetics
Polymorphism, Single Nucleotide
Receptors, Glucocorticoid - genetics
single nucleotide polymorphism
treatment efficacy
variability
Title GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis
URI https://api.istex.fr/ark:/67375/WNG-PBKJNQ2X-N/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fene.13040
https://www.ncbi.nlm.nih.gov/pubmed/27185333
https://www.proquest.com/docview/1805234596
https://www.proquest.com/docview/1805759644
https://www.proquest.com/docview/1808639883
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqIiEuvB-BggxCqJdUefgVcQK0bVXUCCoq9oAU2XEsRe1uqvUuYjlx4c5v5JfgsZNAUUGIWyRPHrZn7G_Gk28QemqUlDlUDeDG0JikSsRSZSJmTNCE6FQVCuKQhyXbPyYHUzrdQM-Hf2ECP8QYcAPL8Os1GLhU9hcjd0sBlDIm4K9DrhYAoqOf1FFwvuidLZrGoHc9qxBk8Yx3ntuLLsGwfroIaJ7HrX7j2b2GPgyfHPJNTnZWS7VTf_6NzfE_-3QdXe0BKX4RNOgG2mjmN9Hlw_7I_Rb6uneEnZI1-Kw7Xc86Ny2tneHWYtlPbKMxBHMxEE8svn_5ZlcKYjv4o_PCAwn42rXhRUjGbfCywz5P3rm97pVdqy009_yuNjxrtpYWaBlaiaE-Umtvo-PdybtX-3FfuyGuSUGSmGhd5EImmhmdMcVYrYyDJkpnnBquJWfKSIc1FDOSFClJZZJpobWpHR7RLMnvoM15N2_uIWyUKGqWcV5TTajMVZrzpOFaKLd6ZDKN0PYwi1XdE5tDfY3TanBw3CBVflgj9GQUPQtsHhcJPfOqMErIxQmkv3FavS_3qjcvXx-Ub7NpVUZoa9CVqrd8W6VQIyIntGARejw2O5uFgxg5b7pVkOFOgpC_ygiHHoXII3Q36OH4QRkHlJW7lm2vTX_uSzUpJ_7i_r-LPkBXHCpkIctxC20uF6vmoUNeS_XIm9gPAiIrww
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqVgIuvB-BAgYh1EuqPBzbkbgA2nZpuxFUrdgLsuw4lqJ2N9VmF7GcuHDnN_JL8NjZQFFBiFskTx62Z-xvxpNvEHpmlJQpVA1gxmQhiRUPpUp4SCnPIqJjlSuIQ44KOjwme-NsvIZerP6F8fwQfcANLMOt12DgEJD-xcrtWgC1jIl12DegordzqA5_kkfBCaNzt7I4BM3reIUgj6e_9dxutAED--kiqHkeubqtZ-ca-rD6aJ9xcrK9mKvt8vNvfI7_26vr6GqHSfFLr0Q30Fo1vYkujbpT91vo6-4htnpW4bPmdDlp7MzU7QTXLZbd3FYaQzwXA_fE7PuXb-1CQXgHf7SOuOcBX9o2PPP5uBWeN9ilylvP176yqXULzR3Fa-ufNVnKFpgZaomhRFLd3kbHO4Oj18OwK98QliQnUUi0zlMuI02NTqiitFTGohOlE5YZpiWjykgLNxQ1kuQxiWWUaK61KS0k0TRK76D1aTOt7iFsFM9LmjBWZppkMlVxyqKKaa7sApLIOEBbq2kUZcdtDiU2TsXKx7GDJNywBuhpL3rmCT0uEnrudKGXkLMTyIBjmXhf7Iq3r_b3infJWBQB2lwpi-iMvxUxlIlISZbTAD3pm63ZwlmMnFbNwsswK0HIX2W4BZCcpwG66xWx_6CEAdBKbcuWU6c_90UMioG7uP_voo_R5eHR6EAcvCn2H6ArFiRSn_S4idbns0X10AKxuXrk7O0Hlh4v3g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqVqq4QHkHChiEUC-p8nBsR5yA7ra0NCoVFXuoZNlxLEXtblab3YrlxIU7v5FfgidOAkUFIW6RPHnYnrG_GU--Qei5UVLGUDWAGZP4JFTclyriPqU8CYgOVaogDnmY0b0Tsj9KRivoZfcvjOOH6ANuYBnNeg0GPtXmFyO3SwGUMibWX18jNOCg0jvHP7mj4ICx8baS0AfFa2mFII2nv_XSZrQG4_rpKqR5Gbg2O8_wBjrtvtklnJxtL-ZqO__8G53jf3ZqA11vESl-5VToJlopJrfQ-mF75n4bfd09xlbLCjytzpfjys5LWY9xWWPZzmyhMURzMTBPzL5_-VYvFAR38IV1wx0L-NK24ZnLxi3wvMJNorz1e-0rq1LX0NwSvNbuWeOlrIGXoZQYCiSV9R10Mhx8eLPnt8Ub_JykJPCJ1mnMZaCp0RFVlObKWGyidMQSw7RkVBlpwYaiRpI0JKEMIs21NrkFJJoG8V20OqkmxX2EjeJpTiPG8kSTRMYqjFlQMM2VXT4iGXpoq5tFkbfM5lBg41x0Ho4dJNEMq4ee9aJTR-dxldCLRhV6CTk7g_w3loiP2a44en2wn72PRiLz0GanK6I1_VqEUCQiJklKPfS0b7ZGCycxclJUCyfDrAQhf5XhFj5yHnvontPD_oMiBjArti1bjTb9uS9ikA2aiwf_LvoErR_tDMW7t9nBQ3TNIkTqMh430ep8tigeWRQ2V48ba_sBCiAulg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=GR+gene+polymorphism+is+associated+with+inter-subject+variability+in+response+to+glucocorticoids+in+patients+with+myasthenia+gravis&rft.jtitle=European+journal+of+neurology&rft.au=Xie%2C+Y&rft.au=Meng%2C+Y&rft.au=Li%2C+H-F&rft.au=Hong%2C+Y&rft.date=2016-08-01&rft.eissn=1468-1331&rft.volume=23&rft.issue=8&rft.spage=1372&rft_id=info:doi/10.1111%2Fene.13040&rft_id=info%3Apmid%2F27185333&rft.externalDocID=27185333
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1351-5101&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1351-5101&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1351-5101&client=summon